Table 1.
Organism/Model | Dose | Form | Administration Route | Effects |
---|---|---|---|---|
Rat/paw edema | 50 and 100 mg/kg | extract | oral | Reduction of carrageenan-induced paw edema formation by 22 or 38% |
Mouse/Th2-mediated airway inflammation in OVA-sensitized animals | 360 mg/kg | extract | i.p. | Reduced amount of eosinophils, neutrophils, and monocytes in BALF and lung tissue |
Rat/cervix cancer | 100 mg/kg | extract | oral | Less NFκB distribution in tissue |
Rat/liver cancer | 100 mg/kg | extract | oral | Decreased NFκB expression |
Rat/ breast cancer/liver cancer cells | 100 mg/kg | extract | oral | Reduced TNF levels |
Rat/saline administration | 50 and 500 mg/kg | extract | oral or i.p. | Reduced PGE2 serum levels |
Rat/saline administration | 500 mg/kg | extract | oral | Reduced TXB2 serum levels |
Rat/paw edema | 25, 50, 100 and 200 mg/kg | extract | oral | Reduced carrageenan-induced paw volume, levels of PGE2, TNF, IL-6, IL-1β, IFNγ, MCP-1, MIP-2, RANTES, and MPO activity and NO levels |
Rat/gastric ulcer | 200 mg/kg | powder | oral | Block of aspirin-induced gastric mucosal lesion formation, abrogation of ulcer with distorted gastric glands, damaged mucosal epithelium, and the formation of cell debris Restoration of normal physiological volume of gastric juice and acidity; reduction of mucosal iNOS activity, TNF, and IL-1β plasma levels |
Mouse/arthritis | 100 and 200 mg/kg | extract | oral | Reduction of collagen II-induced IL-4, IFN-γ, and IL-17 protein and MMP1, 3 and 13 mRNA |
Rat/arthritis | 50, 100 and 200 mg/kg | extract | i.p. | Reduction of collagen II-induced joint temperature and paw thickness, serum levels of cytokines IL-1β, IL-2, IL-6, TNF, and anti-type II collagen antibodies, increased paw removal latency |
Mouse/UVB-irradiated hyperplasia | 1 and 2.5% | extract | oral | UVB-induced reduction of leukocyte infiltration, levels of IL-1β and IL-6 |